RVTYMEDIUM SIGNALFINANCIAL10-K

RVTY experienced broad-based revenue decline with reduced gross profit margins, though the company maintained profitability and reduced debt levels.

The 13.5% revenue decline coupled with an 18.2% drop in gross profit suggests margin compression, indicating either pricing pressure or unfavorable business mix shifts. However, the company's ability to maintain positive net income while reducing total debt by $500 million demonstrates disciplined capital management during a challenging period.

Comparing 2026-02-24 vs 2025-02-25View on EDGAR →
FINANCIAL ANALYSIS

RVTY's financials reflect a contraction across key metrics, with revenue declining 13.5% to $3.3 billion and gross profit falling more sharply at 18.2% to $2.0 billion, indicating margin pressure. The company reduced total debt by 11.3% to $3.9 billion and lowered interest expense accordingly, while cash declined to $920 million amid higher accounts receivable of $745 million. Despite the revenue headwinds, RVTY preserved profitability with net income of $241 million, down a more modest 10.8%.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
-21.9%
$63.6M$49.7M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Cash & Equivalents
Balance Sheet
-20.9%
$1.2B$919.9M

Cash decreased 20.9% — monitor burn rate and upcoming capital needs.

Gross Profit
P&L
-18.2%
$2.4B$2.0B

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Accounts Receivable
Balance Sheet
+17.8%
$632.4M$744.7M

Receivables grew 17.8% — monitor days sales outstanding for collection efficiency.

Revenue
P&L
-13.5%
$3.8B$3.3B

Revenue softened 13.5% — monitor whether this is cyclical or structural.

Total Debt
Balance Sheet
-11.3%
$4.4B$3.9B

Debt reduced 11.3% — deleveraging strengthens balance sheet and reduces financial risk.

Net Income
P&L
-10.8%
$270.4M$241.2M

Net income declined 10.8% — review whether driven by operations, interest costs, or non-recurring items.

LANGUAGE CHANGES
NEW — 2026-02-24
PRIOR — 2025-02-25
ADDED
As of February 20, 2026, there were outstanding 111,799,374 shares of common stock, $1 par value per share.
DOCUMENTS INCORPORA TED BY REFERENCE Portions of Revvity, Inc.
As of December 28, 2025, we employed approximately 11,000 employees.
BioLegend best-in-class antibodies, recombinant proteins, and related reagents, which are used across multiple applications and research areas, including flow cytometry, microscopy, proteogenomics, tissue, cell and protein analysis, cancer research, immunology, cell and gene therapy, stem cell therapy and neuroscience.
TotalSeq reagents offer individual antibodies as well as hashtags for sample pooling and large cocktails for the analysis of hundreds of protein markers.
+7 more — sign up free →
REMOVED
As of February 21, 2025, there were outstanding 120,187,286 shares of common stock, $1 par value per share.
As of December 29, 2024, we employed approximately 11,000 employees.
BioLegend best-in-class antibodies, recombinant proteins, and related reagents are used across multiple applications and research areas, including proteogenomics, tissue, cell and protein analysis, cancer research, immunology, cell and gene therapy, stem cell therapy and neuroscience.
BioLegend s MojoSort for cell separation that complements our fluorophore-antibody conjugates, used for FACS (Fluorescence-activated Cell Sorting), thus covering most cell separation and cell sorting technologies and applications.
BioLegend s catalog of more than 33,000 SKUs, incorporating antibodies and a large collection of antibody conjugates and modifications as well as recombinant proteins, immunoassays, and other supportive reagents and solutions for cell and molecular analysis.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →